JTX-2134

N/A

Report date: 2023/05/17 15:05:26

Base Information

Drug NameJTX-2134

Drug Alias NameJTX-2134

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsLeukocyte immunoglobulin-like receptor B1 inhibitorsT lymphocytes stimulants

TargetsLeukocyte immunoglobulin-like receptor B1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesJounce Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesJounce Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A